ESTRO 2024 - Abstract Book

S1838

Clinical - Mixed sites, palliation

ESTRO 2024

Further, toxicity data following WBRT was collected where available which found reports of fatigue most commonly (17%), as well as hair loss (5%), cognitive impairment (5%), headache (5%), and nausea (5%). However, this data was not prospectively documented systematically.

There was a sharp decline in the total number of patients undergoing WBRT from 2017 onwards; 2012-2016 (n=265) versus 2017-2021 (n=123).

Conclusion:

Despite advances in the treatment of metastatic brain metastases WBRT is still a frequently utilised treatment modality. This audit confirmed that survival after WBRT is reasonable and that it is a well-tolerated treatment in carefully selected patients. Patient factors such as age under 65 years and belonging to a higher RPA prognostication class were significantly associated with improved outcomes. Further work to explore the synergy and toxicity of novel systemic anti-cancer treatments with WBRT and real world data studying the role of hippocampal-avoidance WBRT in the management of cerebral metastases is needed.

Keywords: Whole Brain Radiotherapy, Brain, Metastases

References:

Tsao MN, Lloyd N, Wong RK, Chow E, Rakovitch E, Laperriere N, et al. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev. 2012;2012(4):CD003869.

Mulvenna P, Nankivell M, Barton R, Faivre-Finn C, Wilson P, McColl E, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004-14. Jeene PM, de Vries KC, van Nes JGH, Kwakman JJM, Wester G, Rozema T, et al. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014. Acta Oncol. 2018;57(5):637-43.

315

Mini-Oral

ARREST – A phase I study of SABR for poly-metastatic disease.

Timothy Nguyen 1 , Sherif Ramadan 1 , David A Palma 1 , Mark T Corkum 2 , Melissa O'Neil 1 , Anders Celinski 3 , Hatim Fakir 3 , Andrew Warner 1 , Abhirami Hallock 4 , Rohann J.M Correa 1 , Melody Qu 1 , Michael Lock 1 , Pencilla Lang 1 , Vikram Velker 1 , Glenn S Bauman 1